The Broad Spectrum Receptor Tyrosine Kinase Inhibitor Dovitinib Suppresses Growth of BRAF Mutant Melanoma Cells in Combination with Other Signaling Pathway Inhibitors

BRAF inhibitors have revolutionized treatment of mutant BRAF metastatic melanomas. However, resistance develops rapidly following BRAF inhibitor treatment. We have found that BRAF-mutant melanoma cell lines are more sensitive than wild-type BRAF cells to the small molecule tyrosine kinase inhibitor...

Full description

Saved in:
Bibliographic Details
Published in:Pigment Cell Melanoma Res
Main Authors: Langdon, Casey G., Held, Matthew A., Platt, James T., Meeth, Katrina, Iyidogan, Pinar, Mamillapalli, Ramanaiah, Koo, Andrew B., Klein, Michael, Liu, Zongzhi, Bosenberg, Marcus W., Stern, David F.
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5215495/
https://ncbi.nlm.nih.gov/pubmed/25854919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12376
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items